Bruker (BRKR) Tops Q4 EPS by 3c

Bruker (NASDAQ: BRKR) reported Q4 EPS of $0.58, $0.03 better than the analyst estimate of $0.55. Revenue for the quarter came in at $627.5 million versus the consensus estimate of $598.71 million.

GUIDANCE:

• Bruker sees FY2021 EPS of $1.72-$1.77, versus the consensus of $1.71.
• organic revenue growth of approximately 7% to 9%, and
• a favorable foreign currency revenue tailwind of approximately 4%.

For earnings history and earnings-related data on Bruker (BRKR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c